Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Spectral MedicalEDTXF +0.81%9 5-Year Yield-on-Cost % is 0.00 as of Jul. 24, 2026. GuruFocus rates EDTXF with a GF Score™ of 9/100 and a GF Value™ of $0.65 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 64 Medical Diagnostics & Research companies, Spectral Medical ranks worse than 1562498.44% on this metric.
Spectral Medical's yield on cost for the quarter that ended in Mar. 2026 was 0.00.
The historical rank and industry rank for Spectral Medical's 5-Year Yield-on-Cost % or its related term are showing as below:
EDTXF's 5-Year Yield-on-Cost % is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 2.52 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Spectral Medical (OTCPK:EDTXF) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Spectral Medical 5-Year Yield-on-Cost % Related Terms
EDTXF vs TMO, DHR, IDXX: 5-Year Yield-on-Cost % Comparison
For the Diagnostics & Research subindustry, Spectral Medical's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Spectral Medical 5-Year Yield-on-Cost % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Spectral Medical's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Spectral Medical's 5-Year Yield-on-Cost % falls into.
Spectral Medical 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Spectral Medical (EDTXF) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 24, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Spectral Medical and its competitors. According to the industry distribution chart, Spectral Medical ranks #999999 out of 64 companies in the Medical Diagnostics & Research industry.
Is Spectral Medical's 5-Year Yield-on-Cost % too high?
Spectral Medical's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Spectral Medical ranks #999999 out of 64 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Spectral Medical has a GF Score™ of 9/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Spectral Medical's 5-Year Yield-on-Cost % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Spectral Medical ranks #999999 out of 64 companies for 5-Year Yield-on-Cost %. This places Spectral Medical in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.52. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Diagnostics & Research company?
The median 5-Year Yield-on-Cost % among Medical Diagnostics & Research companies is 2.52, based on 64 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Spectral Medical and its competitors. For the Medical Diagnostics & Research industry, the median 5-Year Yield-on-Cost % is 2.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Spectral Medical's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spectral Medical stock overvalued right now?
Based on GuruFocus' analysis, Spectral Medical (EDTXF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.65, compared to a current price of $0.98 — trading 50.2% above its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Spectral Medical's overall GF Score™ is 9/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Spectral Medical (EDTXF), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Spectral Medical (EDTXF) Overvalued in 2026?
Based on GuruFocus' analysis, Spectral Medical stock appears to be overvalued.
The current stock price of $0.98 is trading 50.2% above its estimated GF Value™ of $0.65.
GuruFocus considers Spectral Medical to be Significantly Overvalued.
Key valuation signals for EDTXF:
5-Year Yield-on-Cost %: 0.00
GF Value™: $0.65 vs. price of $0.98 (50.2% above fair value)
No single metric tells the full story. See the EDTXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Spectral Medical Inc is focused on the development and commercialization of a treatment for septic shock utilizing its endotoxin activity assay (EAA) diagnostic and the Toraymyxin therapeutic. The company also manufactures and sells proprietary reagents. The product line of the company consists of proprietary biochemical, EAA, and instrumentation. Its products include an endotoxin activity assay, a rapid in-vitro diagnostic test used to measure endotoxin levels in blood, and a polymyxin B hemoperfusion device designed to remove endotoxin from the bloodstream. The company's proprietary reagents include recombinant proteins, antibodies, and calibrators used in research and diagnostic applications.
9GF Score
Get the complete analysis for EDTXF
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EDTXF has been successfully added to your 
